Form D · Biotechnology
Implicit Bioscience Ltd
Woolloongabba, C3 · CIK 0001684309
Offering snapshot reported Sep 14, 2020 · SEC filing
- Reported sold
- $65.6K Indefinite offering
- Investors reported
- 2 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Aug 28, 2020 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Sep 14, 2020 | Initial | $65,551 | No comparison | 2 | SEC filing |
| Sep 27, 2019 | Initial | $367,227 | No comparison | 4 | SEC filing |
| Sep 13, 2017 | Initial | $125,000 | No comparison | 3 | SEC filing |
| Sep 16, 2016 | Initial | $210,065 | No comparison | 3 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-375398
Source: Form D, filed Sep 14, 2020. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Peter Ronald Andrews | Director |
| Ian Hector Frazer | Director |
| Peter Camac Huntley Fry | Director |
| Marion Koster | Executive |
| Richard Neil Marsden | Director |
| Garry Llewellyn Redlich | Director, Executive |
| Daniel David Syrdal | Director |
| Brian William Ziegelaar | Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
32 Logan Road
Woolloongabba, C3, QLD 4102
Woolloongabba, C3, QLD 4102